Public Act 103-0245
 
SB1987 EnrolledLRB103 25792 RLC 57149 b

    AN ACT concerning criminal law.
 
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
 
    Section 5. The Illinois Controlled Substances Act is
amended by changing Section 204 as follows:
 
    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
    Sec. 204. (a) The controlled substances listed in this
Section are included in Schedule I.
    (b) Unless specifically excepted or unless listed in
another schedule, any of the following opiates, including
their isomers, esters, ethers, salts, and salts of isomers,
esters, and ethers, whenever the existence of such isomers,
esters, ethers and salts is possible within the specific
chemical designation:
        (1) Acetylmethadol;
        (1.1) Acetyl-alpha-methylfentanyl
    (N-[1-(1-methyl-2-phenethyl)-
    4-piperidinyl]-N-phenylacetamide);
        (2) Allylprodine;
        (3) Alphacetylmethadol, except
    levo-alphacetylmethadol (also known as levo-alpha-
    acetylmethadol, levomethadyl acetate, or LAAM);
        (4) Alphameprodine;
        (5) Alphamethadol;
        (6) Alpha-methylfentanyl
    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
    propanilido) piperidine;
        (6.1) Alpha-methylthiofentanyl
    (N-[1-methyl-2-(2-thienyl)ethyl-
    4-piperidinyl]-N-phenylpropanamide);
        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
        (7.1) PEPAP
    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
        (8) Benzethidine;
        (9) Betacetylmethadol;
        (9.1) Beta-hydroxyfentanyl
    (N-[1-(2-hydroxy-2-phenethyl)-
    4-piperidinyl]-N-phenylpropanamide);
        (10) Betameprodine;
        (11) Betamethadol;
        (12) Betaprodine;
        (13) Clonitazene;
        (14) Dextromoramide;
        (15) Diampromide;
        (16) Diethylthiambutene;
        (17) Difenoxin;
        (18) Dimenoxadol;
        (19) Dimepheptanol;
        (20) Dimethylthiambutene;
        (21) Dioxaphetylbutyrate;
        (22) Dipipanone;
        (23) Ethylmethylthiambutene;
        (24) Etonitazene;
        (25) Etoxeridine;
        (26) Furethidine;
        (27) Hydroxpethidine;
        (28) Ketobemidone;
        (29) Levomoramide;
        (30) Levophenacylmorphan;
        (31) 3-Methylfentanyl
    (N-[3-methyl-1-(2-phenylethyl)-
    4-piperidyl]-N-phenylpropanamide);
        (31.1) 3-Methylthiofentanyl
    (N-[(3-methyl-1-(2-thienyl)ethyl-
    4-piperidinyl]-N-phenylpropanamide);
        (32) Morpheridine;
        (33) Noracymethadol;
        (34) Norlevorphanol;
        (35) Normethadone;
        (36) Norpipanone;
        (36.1) Para-fluorofentanyl
    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
    4-piperidinyl]propanamide);
        (37) Phenadoxone;
        (38) Phenampromide;
        (39) Phenomorphan;
        (40) Phenoperidine;
        (41) Piritramide;
        (42) Proheptazine;
        (43) Properidine;
        (44) Propiram;
        (45) Racemoramide;
        (45.1) Thiofentanyl
    (N-phenyl-N-[1-(2-thienyl)ethyl-
    4-piperidinyl]-propanamide);
        (46) Tilidine;
        (47) Trimeperidine;
        (48) Beta-hydroxy-3-methylfentanyl (other name:
    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
    N-phenylpropanamide);
        (49) Furanyl fentanyl (FU-F);
        (50) Butyryl fentanyl;
        (51) Valeryl fentanyl;
        (52) Acetyl fentanyl;
        (53) Beta-hydroxy-thiofentanyl;
        (54) 3,4-dichloro-N-[2-
    (dimethylamino)cyclohexyl]-N-
    methylbenzamide (U-47700); 
        (55) 4-chloro-N-[1-[2-
    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
    benzenesulfonamide (W-18); 
        (56) 4-chloro-N-[1-(2-phenylethyl)
    -2-piperidinylidene]-benzenesulfonamide (W-15); 
        (57) acrylfentanyl (acryloylfentanyl). 
    (c) Unless specifically excepted or unless listed in
another schedule, any of the following opium derivatives, its
salts, isomers and salts of isomers, whenever the existence of
such salts, isomers and salts of isomers is possible within
the specific chemical designation:
        (1) Acetorphine;
        (2) Acetyldihydrocodeine;
        (3) Benzylmorphine;
        (4) Codeine methylbromide;
        (5) Codeine-N-Oxide;
        (6) Cyprenorphine;
        (7) Desomorphine;
        (8) Diacetyldihydromorphine (Dihydroheroin);
        (9) Dihydromorphine;
        (10) Drotebanol;
        (11) Etorphine (except hydrochloride salt);
        (12) Heroin;
        (13) Hydromorphinol;
        (14) Methyldesorphine;
        (15) Methyldihydromorphine;
        (16) Morphine methylbromide;
        (17) Morphine methylsulfonate;
        (18) Morphine-N-Oxide;
        (19) Myrophine;
        (20) Nicocodeine;
        (21) Nicomorphine;
        (22) Normorphine;
        (23) Pholcodine;
        (24) Thebacon.
    (d) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
hallucinogenic substances, or which contains any of its salts,
isomers and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers is possible within the
specific chemical designation (for the purposes of this
paragraph only, the term "isomer" includes the optical,
position and geometric isomers):
        (1) 3,4-methylenedioxyamphetamine
    (alpha-methyl,3,4-methylenedioxyphenethylamine,
    methylenedioxyamphetamine, MDA);
        (1.1) Alpha-ethyltryptamine
    (some trade or other names: etryptamine;
    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
    3-(2-aminobutyl)indole; a-ET; and AET);
        (2) 3,4-methylenedioxymethamphetamine (MDMA);
        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
    (also known as: N-ethyl-alpha-methyl-
    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
    and MDEA);
        (2.2) N-Benzylpiperazine (BZP);
        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
        (4) 3,4,5-trimethoxyamphetamine (TMA);
        (5) (Blank);
        (6) Diethyltryptamine (DET);
        (7) Dimethyltryptamine (DMT);
        (7.1) 5-Methoxy-diallyltryptamine;
        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
        (9) Ibogaine  (some trade and other names:
    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
    indole; Tabernanthe iboga);
        (10) Lysergic acid diethylamide;
        (10.1) Salvinorin A;
        (10.5) Salvia divinorum (meaning all parts of the
    plant presently classified botanically as Salvia
    divinorum, whether growing or not, the seeds thereof, any
    extract from any part of that plant, and every compound,
    manufacture, salts, isomers, and salts of isomers whenever
    the existence of such salts, isomers, and salts of isomers
    is possible within the specific chemical designation,
    derivative, mixture, or preparation of that plant, its
    seeds or extracts);
        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
        (12) Peyote (meaning all parts of the plant presently
    classified botanically as Lophophora williamsii Lemaire,
    whether growing or not, the seeds thereof, any extract
    from any part of that plant, and every compound,
    manufacture, salts, derivative, mixture, or preparation of
    that plant, its seeds or extracts);
        (13) N-ethyl-3-piperidyl benzilate (JB 318);
        (14) N-methyl-3-piperidyl benzilate;
        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
    (also known as N-hydroxy-alpha-methyl-
    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
        (15) Parahexyl; some trade or other names:
    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
    dibenzo (b,d) pyran; Synhexyl;
        (16) Psilocybin;
        (17) Psilocyn;
        (18) Alpha-methyltryptamine (AMT);
        (19) 2,5-dimethoxyamphetamine
    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
        (20) 4-bromo-2,5-dimethoxyamphetamine
    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
    4-bromo-2,5-DMA);
        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
    Some trade or other names: 2-(4-bromo-
    2,5-dimethoxyphenyl)-1-aminoethane;
    alpha-desmethyl DOB, 2CB, Nexus;
        (21) 4-methoxyamphetamine
    (4-methoxy-alpha-methylphenethylamine;
    paramethoxyamphetamine; PMA);
        (22) (Blank);
        (23) Ethylamine analog of phencyclidine.
    Some trade or other names:
    N-ethyl-1-phenylcyclohexylamine,
    (1-phenylcyclohexyl) ethylamine,
    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
        (24) Pyrrolidine analog of phencyclidine. Some trade
    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
    PHP;
        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
        (26) 2,5-dimethoxy-4-ethylamphetamine
    (another name: DOET);
        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
    (another name: TCPy);
        (28) (Blank);
        (29) Thiophene analog of phencyclidine (some trade
    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
    2-thienyl analog of phencyclidine; TPCP; TCP);
        (29.1) Benzothiophene analog of phencyclidine. Some
    trade or other names: BTCP or benocyclidine;
        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
        (30) Bufotenine (some trade or other names:
    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
    3-(2-dimethylaminoethyl)-5-indolol;
    5-hydroxy-N,N-dimethyltryptamine;
    N,N-dimethylserotonin; mappine);
        (31) (Blank);  
        (32) (Blank);  
        (33) (Blank);  
        (34) (Blank); 
        (34.5) (Blank);  
        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
    (2-methyloctan-2-yl)-6a,7, 
    10,10a-tetrahydrobenzo[c]chromen-1-ol
    Some trade or other names: HU-210; 
        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
    salts, and salts of isomers; Some trade or other  
    names: HU-210, Dexanabinol; 
        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
    Some trade or other names: HU-211;
        (37) (Blank);
        (38) (Blank);
        (39) (Blank);
        (40) (Blank);
        (41) (Blank);
        (42) Any compound structurally derived from
    3-(1-naphthoyl)indole or
    1H-indol-3-yl-(1-naphthyl)methane by substitution at the
    nitrogen atom of the indole ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl whether or not further substituted
    in the indole ring to any extent, whether or not
    substituted in the naphthyl ring to any extent. Examples
    of this structural class include, but are not limited to,
    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
        (43) Any compound structurally derived from
    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    in the pyrrole ring to any extent, whether or not
    substituted in the naphthyl ring to any extent. Examples
    of this structural class include, but are not limited to,
    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
        (44) Any compound structurally derived from
    1-(1-naphthylmethyl)indene by substitution at the
    3-position of the indene ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl whether or not further substituted
    in the indene ring to any extent, whether or not
    substituted in the naphthyl ring to any extent. Examples
    of this structural class include, but are not limited to,
    JWH-176;
        (45) Any compound structurally derived from
    3-phenylacetylindole by substitution at the nitrogen atom
    of the indole ring with alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    in the indole ring to any extent, whether or not
    substituted in the phenyl ring to any extent. Examples of
    this structural class include, but are not limited to,
    JWH-167, JWH-250, JWH-251, and RCS-8;
        (46) Any compound structurally derived from
    2-(3-hydroxycyclohexyl)phenol by substitution at the
    5-position of the phenolic ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not substituted in the
    cyclohexyl ring to any extent. Examples of this structural
    class include, but are not limited to, CP 47, 497 and its
    C8 homologue (cannabicyclohexanol);
        (46.1) Any compound structurally derived from
    3-(benzoyl) indole with substitution at the nitrogen atom
    of the indole ring by an alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl group whether or not further
    substituted in the indole ring to any extent and whether
    or not substituted in the phenyl ring to any extent.
    Examples of this structural class include, but are not
    limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
    48,098), and RCS-4;
        (47) (Blank);
        (48) (Blank);
        (49) (Blank);
        (50) (Blank);
        (51) (Blank);
        (52) (Blank);
        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
    Some trade or other names: 2C-T-7;
        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
    trade or other names: 2C-E;
        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
    trade or other names: 2C-D;
        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
    trade or other names: 2C-C;
        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
    or other names: 2C-I;
        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
    trade or other names: 2C-T-2;
        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
    Some trade or other names: 2C-T-4;
        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
    other names: 2C-H;
        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
    trade or other names: 2C-N;
        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
    trade or other names: 2C-P;
        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
    Some trade or other names: 2C-G;
        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
    phenethylamine referred to in subparagraphs (20.1), (53),
    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
    (53.8), (53.9), and (53.10) including, but not limited to,
    25I-NBOMe and 25C-NBOMe;
        (54) 5-Methoxy-N,N-diisopropyltryptamine;
        (55) (Blank);
        (56) (Blank);
        (57) (Blank);
        (58) (Blank);
        (59) 3-cyclopropoylindole with substitution at the
    nitrogen atom of the indole ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent, whether or not
    substituted on the cyclopropyl ring to any extent:
    including, but not limited to, XLR11, UR144, FUB-144;
        (60) 3-adamantoylindole with substitution at the
    nitrogen atom of the indole ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent, whether or not
    substituted on the adamantyl ring to any extent:
    including, but not limited to, AB-001;
        (61) N-(adamantyl)-indole-3-carboxamide with
    substitution at the nitrogen atom of the indole ring by
    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
    cycloalkylethyl, aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent, whether or not
    substituted on the adamantyl ring to any extent:
    including, but not limited to, APICA/2NE-1, STS-135;
        (62) N-(adamantyl)-indazole-3-carboxamide with
    substitution at a nitrogen atom of the indazole ring by
    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
    cycloalkylethyl, aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent, whether or not
    substituted on the adamantyl ring to any extent:
    including, but not limited to, AKB48, 5F-AKB48;
        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
    with substitution at the nitrogen atom of the indole ring
    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
    cycloalkylethyl, aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent, whether or not
    substituted on the quinoline ring to any extent:
    including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
        (64) 3-(1-naphthoyl)indazole with substitution at the
    nitrogen atom of the indazole ring by alkyl, haloalkyl,
    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent, whether or not
    substituted on the naphthyl ring to any extent: including,
    but not limited to, THJ-018, THJ-2201;
        (65) 2-(1-naphthoyl)benzimidazole with substitution
    at the nitrogen atom of the benzimidazole ring by alkyl,
    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
    aryl halide, alkyl aryl halide,
    1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the benzimidazole ring to any extent, whether or not
    substituted on the naphthyl ring to any extent: including,
    but not limited to, FUBIMINA;
        (66)
    N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
    3-carboxamide with substitution on the nitrogen atom of
    the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
    indazole-3-carboxamide with substitution on the nitrogen
    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, ADB-PINACA, ADB-FUBINACA;
        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
    indole-3-carboxamide with substitution on the nitrogen
    atom of the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent: including, but not
    limited to, ADBICA, 5F-ADBICA;
        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
    3-carboxamide with substitution on the nitrogen atom of
    the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indole ring to any extent: including, but not
    limited to, ABICA, 5F-ABICA;
        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
    methylbutanoate with substitution on the nitrogen atom of
    the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, AMB, 5F-AMB;
        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
    dimethylbutanoate with substitution on the nitrogen atom
    of the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
        (72) Methyl 2-(1H-indole-3-carboxamido)-3-
    methylbutanoate with substitution on the nitrogen atom of
    the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, MMB018, MMB2201, and AMB-CHMICA;
        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
    dimethylbutanoate with substitution on the nitrogen atom
    of the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, MDMB-CHMICA;
        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
    indazole-3-carboxamide with substitution on the nitrogen
    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any     extent: including, but not
    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
    3-carboxamide with substitution on the nitrogen atom of
    the indole ring by alkyl, haloalkyl, alkenyl,
    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
    halide, 1-(N-methyl-2-piperidinyl)methyl, or
    2-(4-morpholinyl)ethyl, whether or not further substituted
    on the indazole ring to any extent: including, but not
    limited to, APP-PICA and 5-fluoro-APP-PICA;
        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
    4-AcO-DMT;
        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
    name 5-MeO-MIPT;
        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
    (4-HO-MiPT);
        (82) Fluorophenylpiperazine;
        (83) Methoxetamine;
        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
    ethcathinone).
    (e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers
whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
        (1) mecloqualone;
        (2) methaqualone; and
        (3) gamma hydroxybutyric acid.
    (f) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts, isomers, and salts of isomers:
        (1) Fenethylline;
        (2) N-ethylamphetamine;
        (3) Aminorex (some other names:
    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
    4-5-dihydro-5-phenyl-2-oxazolamine) and its
    salts, optical isomers, and salts of optical isomers;
        (4) Methcathinone (some other names:
    2-methylamino-1-phenylpropan-1-one;
    Ephedrone; 2-(methylamino)-propiophenone;
    alpha-(methylamino)propiophenone; N-methylcathinone;
    methycathinone; Monomethylpropion; UR 1431) and its
    salts, optical isomers, and salts of optical isomers;
        (5) Cathinone (some trade or other names:
    2-aminopropiophenone; alpha-aminopropiophenone;
    2-amino-1-phenyl-propanone; norephedrone);
        (6) N,N-dimethylamphetamine (also known as:
    N,N-alpha-trimethyl-benzeneethanamine;
    N,N-alpha-trimethylphenethylamine);
        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
        (9) Halogenated amphetamines and
    methamphetamines - any compound derived from either
    amphetamine or methamphetamine through the substitution
    of a halogen on the phenyl ring, including, but not
    limited to, 2-fluoroamphetamine, 3-
    fluoroamphetamine and 4-fluoroamphetamine; 
        (10) Aminopropylbenzofuran (APB):
    including 4-(2-Aminopropyl) benzofuran, 5-
    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
        (11) Aminopropyldihydrobenzofuran (APDB):
    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
        (12) Methylaminopropylbenzofuran
    (MAPB): including 4-(2-methylaminopropyl)
    benzofuran, 5-(2-methylaminopropyl)benzofuran,
    6-(2-methylaminopropyl)benzofuran
    and 7-(2-methylaminopropyl)benzofuran. 
    (g) Temporary listing of substances subject to emergency
scheduling. Any material, compound, mixture, or preparation
that contains any quantity of the following substances:
        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
    (benzylfentanyl), its optical isomers, isomers, salts, and
    salts of isomers;
        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
    phenylpropanamide (thenylfentanyl), its optical isomers,
    salts, and salts of isomers.
    (h) Synthetic cathinones. Unless specifically excepted,
any chemical compound which is not approved by the United
States Food and Drug Administration or, if approved, is not
dispensed or possessed in accordance with State or federal
law, not including bupropion, structurally derived from
2-aminopropan-1-one by substitution at the 1-position with
either phenyl, naphthyl, or thiophene ring systems, whether or
not the compound is further modified in one or more of the
following ways:
        (1) by substitution in the ring system to any extent
    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
    halide substituents, whether or not further substituted in
    the ring system by one or more other univalent
    substituents. Examples of this class include, but are not
    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
        (2) by substitution at the 3-position with an acyclic
    alkyl substituent. Examples of this class include, but are
    not limited to, 2-methylamino-1-phenylbutan-1-one
    (buphedrone); or
        (3) by substitution at the 2-amino nitrogen atom with
    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
    inclusion of the 2-amino nitrogen atom in a cyclic
    structure. Examples of this class include, but are not
    limited to, Dimethylcathinone, Ethcathinone, and
    a-Pyrrolidinopropiophenone (a-PPP); or
    Any other synthetic cathinone which is not approved by the
United States Food and Drug Administration or, if approved, is
not dispensed or possessed in accordance with State or federal
law.
    (i) Synthetic cannabinoids or piperazines. Any synthetic
cannabinoid or piperazine which is not approved by the United
States Food and Drug Administration or, if approved, which is
not dispensed or possessed in accordance with State and
federal law.
    (j) Unless specifically excepted or listed in another
schedule, any chemical compound which is not approved by the
United States Food and Drug Administration or, if approved, is
not dispensed or possessed in accordance with State or federal
law, and is derived from the following structural classes and
their salts:
        (1) Benzodiazepine class: A fused 1,4-diazepine and
    benzene ring structure with a phenyl connected to the
    1,4-diazepine ring, with any substitution(s) or
    replacement(s) on the 1,4-diazepine or benzene ring, any
    substitution(s) on the phenyl ring, or any combination
    thereof. Examples of this class include but are not
    limited to: Clonazolam, Flualprazolam; or
        (2) Thienodiazepine class: A fused 1,4-diazepine and
    thiophene ring structure with a phenyl connected to the
    1,4-diazepine ring, with any substitution(s) or
    replacement(s) on the 1,4-diazepine or thiophene ring, any
    substitution(s) on the phenyl ring, or any combination
    thereof. Examples of this class include but are not
    limited to: Etizolam.
(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
8-14-18.)